Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II axitinib study in metastatic renal cell cancer unsuitable for nephrectomy
ISRCTN72679844Phase 2Completed
- Sponsor
- The Institute of Cancer Research
- Start
- Sep 2012
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of axitinib in renal cell carcinoma (RCC), sponsored by The Institute of Cancer Research. Primary endpoint: Freedom from progression at 6 months. Started Sep 2012; status: completed.
02
Drugs
axitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ISRCTN72679844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN72679844.